ESAB Corporation (ESAB): what the price requires
At today's price, ESAB Corporation (ESAB) is priced for +6.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/ESAB
Headline
| Field | Value |
|---|---|
| Ticker | ESAB |
| Company | ESAB Corporation |
| Current price | $86.72/sh |
| Composition | Equipment 34% / Consumables 66% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 7.4% |
| Operating margin today | 14.5% |
| Margin compression implied | -7.1pp |
| Implied growth | 6.8% |
| Multiple paid | 15x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 9% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.2pp.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.63σ |
| cohort percentile (of 225 peers) | 23 |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 2.35x | 5 | expensive |
| Earnings | 3.37x | 4 | expensive |
| Relative | 1.14x | 3 | expensive |
| Growth | 0.99x | 3 | justifies |
Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.
Per-Model Detail (n=15)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $87.46 | 0.99x | yes | FCF base $0.2B, growth 7% (input: historical growth), terminal g 4.0%, WACC 7.7%, 6yr projection |
| DCF Exit Multiple | Growth | $89.81 | 0.97x | yes | Exit EV/EBITDA: 11.3x / 13.3x / 15.3x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $70.56 | 1.23x | yes | P/E 18x (static sector reference · 2026-04), scenarios: 15.0x / 18.0x / 21.0x (bear / base = reference held flat / bull), EV/EBITDA 12x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $36.53 | 2.37x | yes | BV/sh $35.76, ROE (TTM) 9.5%, ke 9.3% |
| Two-Stage Excess Return | Asset | $36.92 | 2.35x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $69.63 | 1.25x | yes | Rev $2.9B, growth 7% (input: historical growth; tapered), Terminal P/S: 1.5x / 1.8x / 2.1x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $46.86 | 1.85x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.39B × (1−20%) / WACC 7.7% → EPV (no growth) |
| Residual Income | Asset | $36.99 | 2.34x | yes | BV $35.76 + 5yr PV of (ROE (TTM) 9.5% − Kₑ 9.3%) × BV; BV grows 6.1%/yr |
| Graham Number | Asset | $51.92 | 1.67x | yes | √(22.5 × EPS $3.35 × BVPS $35.76) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $76.13 | 1.14x | yes | EBITDA $0.48B × sector EV/EBITDA 12.0x |
| FCF Yield | Earnings | $20.00 | 4.34x | yes | FCF $218.4M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $17.26 | 5.02x | yes | SBC-adj FCF $0.20B (FCF $0.22B − SBC $0.02B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $2.81 | 30.86x | yes | EPS $3.35 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median) |
| ROIC-Justified P/B | Asset | $10.03 | 8.65x | yes | BV $35.76 × (ROIC 2.2% / WACC 7.7%) |
| P/Sales Sector | Relative | $118.75 | 0.73x | yes | Revenue $2.91B × sector P/S 2.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $36.22 | 2.39x | yes | EPS $3.35 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $1.0b |
| Net debt / NOPAT (after-tax) | 3.11x |
| Net debt / operating income (pre-tax) | 2.48x |
| Share count CAGR (dilution) | 0.5% |
| Burning cash | no |
Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.
Bullet Takeaways
- ESAB is a fabrication-technology company whose revenue is about two-thirds recurring consumables, a razor-and-blade structure where every installed welding machine drives repeat filler-metal demand, supporting a margin-expansion track record.
- The biggest specific risk is that the price embeds roughly 14% earnings growth while core organic growth was negative 1% last quarter, so the multiple is paying for acquisitions and margin self-help rather than the existing base, with EBITDA margin already down 80 basis points on integration dilution.
- What to watch next is whether organic growth reaccelerates and the recent acquisitions (EWM, Aktiv, and the closing Eddyfi deal) integrate without further margin drag, against moderate net debt of about 2.6 times operating income.
Bull Case
Start with the balance sheet, because it is what lets ESAB run the strategy it is running. Net debt sits at about $1.03 billion, roughly 2.6 times trailing operating income, a moderate load that leaves room to keep acquiring without straining the business. That capacity is being used: in 2026 alone the company has closed the EWM equipment acquisition and the Aktiv medical-gas business, with the Eddyfi Technologies deal expected to close mid-year. A manageable leverage profile is what funds a serial-acquisition playbook, and ESAB is deploying it to broaden from welding into adjacent fabrication-technology and inspection markets. Management's confidence shows in reiterating full-year guidance even as it integrates several deals at once.
The business model underneath is the quiet strength: consumables, not equipment, carry the company. ESAB describes itself as providing "fabrication technology advanced equipment, consumables, gas control equipment, related robotics and digital solutions," and consumables are about two-thirds of the mix. That is a razor-and-blade structure. The welding machines are sold once; the filler metals and consumables they burn through are bought repeatedly, which gives the revenue base a recurring, lower-cyclicality character that a pure equipment maker lacks. Every installed ESAB machine in the field is a stream of consumable demand, and that installed base compounds over time.
The margin and earnings trajectory support the premium the market assigns. Core adjusted EBITDA rose 6% to $136 million in the quarter on record sales of $746 million, and the company has a multi-year record of pulling its operating margin higher through its business-improvement system. The operating margin near 13.5% has room to expand as recent acquisitions are integrated and their costs are rationalized. On the valuation lenses the price reaches only what the growth-discounted-cash-flow method supports, which is the market paying for ESAB to keep compounding earnings through the combination of recurring consumables, margin self-help, and disciplined M&A. For a diversified fabrication-technology platform with a sticky installed base, that is a coherent durability bet.
Bear Case
The structural truth a holder has to sit with is that the price embeds about 14% earnings growth while the underlying business shrank organically last quarter. Record first-quarter sales of $746 million looked like 10% growth on a reported basis, but that figure was carried by acquisitions and currency; core organic growth was actually negative 1%. The multiple is pricing what acquisitions might deliver, not what the existing business is producing on its own. A growth multiple sitting on flat-to-declining organic volume is the central tension here: strip out the deals, and the demand for ESAB's products softened, which is exactly what a cyclical industrial supplier shows when its end markets cool.
The margin direction added to the concern. Core adjusted EBITDA margin fell 80 basis points year over year to 19.0%, with the company citing dilution from a recent acquisition and additional costs tied to conflict in the Middle East. Buying growth through M&A often comes with lower-margin businesses that take time to bring up to standard, and the integration drag is visible now while the promised synergies are still in the future. The reliance on acquisitions to show top-line growth means the company has to keep finding and integrating deals to sustain the trajectory the price assumes, and each one carries execution risk the existing base does not.
The demand cyclicality is the underlying exposure that the recurring-consumables story only partly offsets. ESAB's products go into welding and fabrication across construction, energy, and general industry, and the 10-K is candid that if "spending in those sectors may substantially decrease, which could reduce demand for our products and have an adverse impact on our revenues." Net debt at 2.6 times operating income is not alarming, but it is real leverage on a business whose organic volume just turned negative, and the acquisition pipeline that drives the headline growth is itself debt- and capital-funded. With the price reaching only the growth-DCF lens while asset value, earnings power, and peer multiples all read rich, the bear case is direct: the valuation requires durable double-digit earnings growth, the organic engine is not currently delivering it, and the gap is being filled by acquisitions whose integration is already pressuring the margin.
Valuation
The price is making a growth bet that the latest organic numbers do not yet support. At roughly 18 times trailing operating income, with an operating margin near 13.5%, the price embeds about 14% growth in operating profit. For a fabrication-technology company that just posted negative 1% core organic growth, that is a demanding assumption, and it tells you the multiple is paying for the acquisition pipeline and margin self-help to deliver the growth the existing base did not.
The methods agree the price is full on a static basis. Asset value, earnings power, and peer multiples all price ESAB well below its current quote, and only the cash-flow-growth lens reaches it. When only the growth lens supports the price, the bet is durability of compounding that the static frames structurally cannot credit. The right interpretation here is a quality-industrial premium: ESAB's recurring consumables base and its record of margin expansion justify trading above the trailing earnings, but the premium is real and it depends on the growth materializing. The earnings-power lens reading especially rich is the caution flag, it says the price is well ahead of what current profitability supports, so the durability of the compounding is doing nearly all the work.
Solvency is moderate and is the lever the acquisition strategy pulls. Net debt is about $1.03 billion, roughly 2.6 times trailing operating income, which gives ESAB room to keep acquiring but is genuine leverage on a business whose organic volume just softened. The recent margin compression, core adjusted EBITDA margin down 80 basis points to 19.0% on integration dilution and Middle East conflict costs, shows the near-term cost of the deal-driven growth. The decisive variable for the price is whether the durable-compounding thesis holds: the consumables base provides recurring demand and the business-improvement system has a track record of lifting margins, but with organic growth flat-to-negative and the multiple reaching only the growth lens, the price requires the acquisitions to integrate cleanly and the organic engine to reaccelerate.
Catalysts
The Q1 2026 report, released in early May, was the central recent catalyst and it captured the company's dual narrative. Record first-quarter sales of $746 million rose 10% on a reported basis but fell 1% on a core organic basis, the gap between the headline and the underlying being acquisitions and currency. GAAP net income from continuing operations was $50 million, or $0.82 per diluted share. Core adjusted EBITDA rose 6% to $136 million, though the margin slipped 80 basis points to 19.0% on integration dilution and added costs tied to Middle East conflict. The company reiterated its full-year 2026 outlook.
Acquisitions are the forward engine and the recent activity is dense. ESAB has closed the EWM equipment business and the Aktiv medical-gas business in 2026, with the Eddyfi Technologies inspection acquisition expected to close mid-year. The pattern is a deliberate expansion from core welding into adjacent fabrication-technology, gas-control, and inspection markets, funded by the company's moderate balance sheet.
Into the next several quarters, the figures to watch are organic growth, since the reacceleration of the existing base is what would validate the premium the price assigns, the EBITDA margin trajectory as the recent deals are integrated and their dilution works through, and the closing and early performance of the Eddyfi acquisition. End-market demand across construction, energy, and general industry is the underlying cyclical driver. The cleanest read on whether the durable-compounding thesis is intact will be a return to positive organic growth alongside margin recovery.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- RRX (REGAL REXNORD CORP)
- (no filing in the citation store)
- GTES (Gates Industrial Corporation plc)
- (no filing in the citation store)
- TKR (TIMKEN CO)
- (no filing in the citation store)
- MOG-A (MOOG Inc.)
- (no filing in the citation store)
- HLIO (HELIOS TECHNOLOGIES, INC.)
- (no filing in the citation store)
- GRC (The Gorman-Rupp Company)
- (no filing in the citation store)
- FLS (FLOWSERVE CORP)
- (no filing in the citation store)
- CW (CURTISS-WRIGHT CORPORATION)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Q1 2026 earnings release